Literature DB >> 16253582

Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.

Sunil V Rao1, Kristi O'Grady, Karen S Pieper, Christopher B Granger, L Kristin Newby, Frans Van de Werf, Kenneth W Mahaffey, Robert M Califf, Robert A Harrington.   

Abstract

Bleeding is a complication of current therapies for acute coronary syndrome (ACS). No studies have examined the effect of bleeding events on clinical outcomes. We analyzed pooled data from 4 multicenter, randomized clinical trials of patients who had ACS (n = 26,452) to determine an association between bleeding severity as measured by the GUSTO scale and 30-day and 6-month mortality rates using Cox proportional hazards modeling that incorporated bleeding as a time-dependent covariate. The analysis was repeated to examine procedure- and non-procedure-related bleeding and after censoring at the time of coronary artery bypass grafting. Of all the patients included, 27.6% had > or =1 bleeding episode. Patients who bled were older and sicker at presentation than were those who did not bleed. Unadjusted rates of 30-day and 6-month mortality increased as bleeding severity increased. There were stepwise increases in the adjusted hazards of 30-day mortality (mild bleeding, hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.3 to 1.9; moderate bleeding, HR 2.7, 95% CI l 2.3 to 3.4; severe bleeding, HR 10.6, 95% CI 8.3 to 13.6) and 6-month mortality (mild bleeding, HR 1.4, 95% CI 1.2 to 1.6; moderate bleeding, HR 2.1, 95% CI 1.8 to 2.4; severe bleeding, HR 7.5, 95% CI 6.1 to 9.3) as bleeding severity increased. Results were consistent after censoring for coronary artery bypass grafting and for procedure- and non-procedure-related bleeds. In conclusion, the GUSTO bleeding classification identifies patients who are at risk for short- and long-term adverse events. Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16253582     DOI: 10.1016/j.amjcard.2005.06.056

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  116 in total

1.  Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Renger G Tiessen; André A van Vliet; Robert R Fales; Robert Keller; Bo Yang; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-09-21       Impact factor: 2.953

Review 2.  Ubiquitin-free routes into the proteasome.

Authors:  M A Hoyt; P Coffino
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

3.  Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome.

Authors:  Diego Castini; Simone Persampieri; Ludovico Sabatelli; Massimo Erba; Giulia Ferrante; Federica Valli; Marco Centola; Stefano Carugo
Journal:  Heart Vessels       Date:  2019-04-10       Impact factor: 2.037

4.  Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry.

Authors:  Bhaskar Bhardwaj; John A Spertus; Kevin F Kennedy; W Schuyler Jones; David Safley; Thomas T Tsai; Herbert D Aronow; Amit N Vora; Yashashwi Pokharel; Arun Kumar; Robert R Attaran; Dmitriy N Feldman; Ehrin Armstrong; Anand Prasad; Bruce Gray; Adam C Salisbury
Journal:  JACC Cardiovasc Interv       Date:  2019-06-24       Impact factor: 11.195

Review 5.  New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction.

Authors:  Eric R Bates
Journal:  Curr Cardiol Rep       Date:  2007-07       Impact factor: 2.931

Review 6.  Contemporary issues on clopidogrel therapy.

Authors:  Giuseppe Patti; Germano Di Sciascio
Journal:  Intern Emerg Med       Date:  2009-01-08       Impact factor: 3.397

Review 7.  Antiplatelet agents in clinical practice and their haemorrhagic risk.

Authors:  Paolo Gresele
Journal:  Blood Transfus       Date:  2013-05-09       Impact factor: 3.443

8.  The bleeding risk score as a mortality predictor in patients with acute coronary syndrome.

Authors:  José Carlos Nicolau; Humberto Graner Moreira; Luciano Moreira Baracioli; Carlos Vicente Serrano; Felipe Galego Lima; Marcelo Franken; Roberto Rocha Giraldez; Fernando Ganem; Roberto Kalil Filho; José Antônio Franchini Ramires; Roxana Mehran
Journal:  Arq Bras Cardiol       Date:  2013-11-12       Impact factor: 2.000

9.  TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.

Authors:  Connie N Hess; Sunil V Rao; David F Kong; Julie M Miller; Kevin J Anstrom; Olivier F Bertrand; Jean-Philippe Collet; Mark B Effron; Benjamin C Eloff; Emmanuel O Fadiran; Andrew Farb; Ian C Gilchrist; David R Holmes; Alice K Jacobs; Prashant Kaul; L Kristin Newby; David R Rutledge; Dale R Tavris; Thomas T Tsai; Roseann M White; Eric D Peterson; Mitchell W Krucoff
Journal:  Am Heart J       Date:  2013-03       Impact factor: 4.749

10.  Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Robert Giugliano; Christopher B Granger; Kenneth W Mahaffey; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa-Filho; Marcia M Barbosa; Maria da Consolacao V Moreira; Renato A K Kalil; Marildes Freitas; Joao Carlos de Campos Guerra; Marcio Vinicius Lins Barros; Thiago da Rocha Rodrigues; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.